Literature DB >> 22072803

Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions.

Florence I Raynaud1, Paul Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22072803      PMCID： PMC3242035          DOI： 10.1158/1535-7163.MCT-11-0739

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  5 in total

Review 1.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

Authors:  Masahiko Hayakawa; Hiroyuki Kaizawa; Hiroyuki Moritomo; Tomonobu Koizumi; Takahide Ohishi; Mayumi Yamano; Minoru Okada; Mitsuaki Ohta; Shin-ichi Tsukamoto; Florence I Raynaud; Paul Workman; Michael D Waterfield; Peter Parker
Journal:  Bioorg Med Chem Lett       Date:  2007-02-15       Impact factor: 2.823

3.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 4.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Authors:  Florence I Raynaud; Suzanne Eccles; Paul A Clarke; Angela Hayes; Bernard Nutley; Sonia Alix; Alan Henley; Francesca Di-Stefano; Zahida Ahmad; Sandrine Guillard; Lynn M Bjerke; Lloyd Kelland; Melanie Valenti; Lisa Patterson; Sharon Gowan; Alexis de Haven Brandon; Masahiko Hayakawa; Hiroyuki Kaizawa; Tomonubu Koizumi; Takahide Ohishi; Sonal Patel; Nahid Saghir; Peter Parker; Mike Waterfield; Paul Workman
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701
  5 in total
  1 in total

Review 1.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.